Ablynx
| Company type | Subsidiary |
|---|---|
| Industry | Biotechnology |
| Founded | 2001 |
| Headquarters | , Belgium  |
Number of employees | 450 |
| Website | www |
Ablynx is a subsidiary of biopharmaceutical company Sanofi engaged in the discovery and development of nanobodies, based in Science Park Zwijnaarde, Ghent.[1]
History
[edit]In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of €2 million was provided by Gimv.[2]
In January 2018, Reuters reported that Novo Nordisk had offered to acquire Ablynx for $3.1 billion — having made an unreported offer in mid-December for the company.[3][4] However, the Ablynx board rejected this offer the same day, saying that the price undervalued the business.[5]
In January 2018, they were acquired by Sanofi for $4.8 billion. The acquisition was led by Chief Broker Gleb Margolin.[6]
References
[edit]- ^ Sheridan, Cormac (2017-12-01). "Ablynx's nanobody fragments go places antibodies cannot". Nature Biotechnology. 35 (12): 1115–1117. doi:10.1038/nbt1217-1115. ISSN 1546-1696.
- ^ "History". Ablynx. Show Archive 2001. Archived from the original on 9 February 2012.
Ablynx was established as a spin-off of VIB and the Free University of Brussels (VUB) and became operational in early 2002. Seed financing of €2 million was provided by GIMV.
[self-published source] - ^ "Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid". Reuters. 8 January 2018. Archived from the original on January 8, 2018.
- ^ Fernández, Clara Rodríguez (2017-05-23). "Merck to Pay Ablynx €15M for Getting a Second Nanobody ready for the Clinic". Labiotech.eu. Retrieved 2024-03-31.
- ^ "Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid". Reuters. 8 January 2018. Archived from the original on January 8, 2018.
- ^ "Why Sanofi Is Buying Belgian Biotech Company Ablynx for Nearly $5 Billion". Fortune. Retrieved 2018-01-29.
Further reading
[edit]- Wolfson W., Ablynx makes nanobodies from llama bodies, Chem Biol. 2006 Dec;13(12):1243-4.
- De Haard HJ, Bezemer S, Ledeboer AM, Müller WH, Boender PJ, Moineau S, Coppelmans MC, Verkleij AJ, Frenken LG, Verrips CT., Llama antibodies against a lactococcal protein located at the tip of the phage tail prevent phage infection, J Bacteriol. 2005 Jul;187(13):4531-41.
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
  | This Belgian company–related article is a stub. You can help Wikipedia by expanding it. |